Study provides vital information regarding four diagnostic PD-L1 assays

A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer, announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research on April 19.

View article:
Study provides vital information regarding four diagnostic PD-L1 assays

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share